Drugs / ATUZAGINSTAT
ATUZAGINSTAT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03823404 | Mar 2019 → Jan 2022 | Alzheimer disease | Cortexyme Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03418688 Comparator | Mar → Oct 2018 | Alzheimer disease | Cortexyme Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03331900 Comparator | Dec 2017 → Feb 2018 | — | Cortexyme Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATUZAGINSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095230 ↗ |
| Known as | COR388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03418688 ↗ |
| Known as | COR388 HCl | “Study of COR388 HCl in Healthy Subjects” NCT03331900 ↗ |
| Modality | Small molecule | — CHEMBL5095230 ↗ |
| Route | Oral | “Administered as oral capsule” NCT03331900 ↗ |